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ABSTRACT:
Introduction: In assisted reproductive technology, aneuploidy is considered a primary cause of 
failed embryo implantation. This has led to the implementation of preimplantation genetic testing 
for aneuploidy in some clinics. The prevalence of aneuploidy and the use of aneuploidy screening 
during preimplantation genetic testing for inherited disorders has not previously been reviewed. 
Here, we systematically review the literature to investigate the prevalence of aneuploidy in 
blastocysts derived from patients carrying or affected by an inherited disorder, and whether 
screening for aneuploidy improves clinical outcomes. Material and methods: PubMed and 
Embase were searched for articles describing preimplantation genetic testing for monogenic 
disorders and/or structural rearrangements in combination with preimplantation genetic testing for 
aneuploidy. Original articles reporting aneuploidy rates at the blastocyst stage and/or clinical 
outcomes (Positive human chorionic gonadotropin, gestational sacs/implantation rate, fetal 
heartbeat/clinical pregnancy, ongoing pregnancy, miscarriage, or live birth/delivery rate on a per 
transfer basis) were included. Case studies were excluded. Results: Of the 26 identified studies, 
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not receiving aneuploidy screening, and the remaining were case series. In weighted analysis, 34.1 
% of 7749 blastocysts were aneuploid. Screening for aneuploidy reduced the proportion of 
embryos suitable for transfer, thereby increasing the risk of experiencing a cycle without 
transferable embryos. In pooled analysis the percentage of embryos suitable for transfer was 
reduced from 57.5 to 37.2 % following screening for aneuploidy. Among cohort studies, one 
reported significantly improved pregnancy and birth rates but did not control for confounding, one 
did not report any statistically significant difference between groups, and one properly designed 
study concluded that preimplantation genetic testing for aneuploidy enhanced the chance of 
achieving a pregnancy while simultaneously reducing the chance of miscarriage following single 
embryo transfer. Conclusion: On average aneuploidy is detected in 34 % of embryos when 
performing a single blastocyst biopsy derived from patients carrying or affected by an inherited 
disorder. Accordingly, when screening for aneuploidy, the risk of experiencing a cycle with no 
transferable embryos increases. Current available data on the clinical effect of preimplantation 
genetic testing for aneuploidy performed concurrently with preimplantation genetic testing for 
inherited disorders is sparse, rendering the clinical effect from preimplantation genetic testing for 
aneuploidy difficult to access.
Keywords 
Preimplantation genetic testing, Clinical outcomes, Aneuploidy screening, Comprehensive 
chromosome screening, Systematic review, preimplantation genetic diagnosis; preimplantation 
screening
Abbreviations: 
aCGH array comparative genomic hybridization
ART assisted reproductive technology 
ESHRE European Society for Human Reproduction and Embryology
FISH fluorescence in situ hybridization
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PGT  preimplantation genetic testing
PGT-A PGT for aneuploidy
PGT-M PGT for monogenic disorders
PGT-SR  PGT for structural rearrangements
PRISMA Preferred reporting items for systematic reviews and meta-analyses
Key message: 
One third of embryos derived from patients carrying or affected by an inherited disorder are 
aneuploid. Hence, prioritizing embryos by ploidy status should in theory improve clinical success 
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INTRODUCTION
Preimplantation genetic testing (PGT) is defined as genetic testing of biopsied material from in 
vitro fertilized pre-implantation embryos from couples carrying or affected by a hereditary 
disorder with the aim of identifying unaffected embryos for transfer. The first case of PGT for an 
inherited disorder was reported by Handyside et al. in 1989 on a couple at risk of transmitting an 
X-linked recessive disease.1 Gender selection was performed on biopsied material from cleavage 
stage embryos by Sanger sequencing followed by transfer of female embryos. Shortly thereafter, 
Sanger sequencing was adapted for direct analysis of monogenic mutations,2 and increased 
diagnostic accuracy was obtained by simultaneous analysis of short tandem repeats.3 
Technological developments led to the introduction of fluorescence in situ hybridization (FISH), 
array comparative genomic hybridization (aCGH), single nucleotide polymorphism arrays, 
karyomapping and next generation sequencing, making PGT possible not only for monogenetic 
disorders but also for chromosomal insertions, duplications, deletions and translocations. PGT 
performed for monogenic diseases and chromosomal structural rearrangements are referred to as 
PGT-M and PGT-SR, respectively.4 Based on data collected from transfer of 6277 embryos in 
4025 PGT cycles by the European Society of Human Reproduction and Embryology (ESHRE) 
PGT consortium, PGT for inherited diseases is currently performed with clinical implantation 
rates (fetal heartbeat/embryo transferred), clinical pregnancy rates (positive heartbeat/embryo 
transfer) and delivery rates (delivery/embryo transfer) of 23, 31 and 25 %, respectively.5 
The current gold standard for prioritization of embryos for transfer during assisted reproductive 
technology (ART) is based upon morphological and developmental assessment of individual 
embryos sometimes aided by time-lapse imaging,6 which is biased by its inherently subjective 
scoring systems.7 It has been acknowledged that aneuploidy is common in human preimplantation 
embryos, affecting approximately 25 % of embryos derived from young women, and increases 
with female age in women receiving ART.8 Furthermore, aneuploidy is prevalent in products of 
conception from miscarriages.9 Altogether, these facts indicate that selection against aneuploidy 
could benefit clinical outcomes. Although some degree of correlation between the morphology 
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on embryo morphology alone.14,15 Preimplantation genetic testing for aneuploidy (PGT-A) is 
numerical chromosomal analysis of biopsied cells from embryos with the purpose of transferring 
euploid embryos and has previously been used in ART in order to optimize clinical outcomes on 
indications such as advanced maternal age, repeated implantation failure, recurrent miscarriages 
and severe male factor infertility. PGT-A was initially performed by FISH (PGT-A version 1.0), 
which allowed the enumeration of a limited number of chromosomes (originally limited to 
chromosome Y, X, 13, 18 and 21), on biopsies from cleavage stage embryos.16 Despite the 
expectations that cleavage stage biopsy and FISH would enhance clinical outcomes, numerous 
randomized controlled trials failed to show any improvements of live birth rates and even showed 
decreased live birth rates in women of advanced maternal age.17 
The lack of clinical effect of PGT-A version 1.0 was attributed to a variety of factors, such as the 
limited number of chromosomes examined by FISH, since aneuploidy may affect all 
chromosomes.18,19 Further,  cleavage stage embryos are more prone to mosaicism  and aneuploidy 
than blastocysts,14,20,21 and hence does not accurately predict the chromosomal profile of the 
resulting blastocyst.22,23 Finally, a negative impact on embryo implantation potential seems to be 
caused by biopsy at the cleavage stage compared with biopsy at the blastocyst stage.24,25 Hence, 
FISH and cleavage stage biopsy are now rarely used as tools for PGT-A, with laboratories 
switching to biopsy at the blastocyst stage and to techniques that allow screening of the entire 
chromosome set, such as aCGH, single nucleotide polymorphism array (later also commercialized 
as karyomapping), and next generation sequencing, also referred to as PGT-A version 2.0 and 
comprehensive chromosome screening. Importantly, although the mentioned techniques allow 
screening of the entire chromosome set, they all have their own limitation. One of the more 
common problems is the detection of sequence-identical chromosomal duplications, such as 
mitotic trisomies or uniparental disomy.  
The combination of comprehensive chromosome screening and blastocyst biopsy was by some 
expected to be able to succeed where PGT-A version 1.0 failed. Initially, a systematic review and 
a meta-analysis independently concluded that comprehensive chromosome screening  enhanced 
clinical outcomes in patients with normal ovarian reserve.26,27 However, others claimed that the 
small size of the limited number of RCTs currently published, did not justify the use of 
comprehensive chromosome screening in clinical practice. 28 A recent multicenter study 
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morphological analysis showed an effect of PGT-A in older patients (35-40 years) only.29 Thus, a 
recent consensus report from the American Society of Reproductive Medicine stated that “At 
present, however, there is insufficient evidence to recommend the routine use of blastocyst biopsy 
with aneuploidy testing in all infertile patients”.30 Recently, and published after the publication of 
the statement by the American Society of Reproductive Medicine, a large historical cohort study 
reported a statistically significant improvement on live births/cycle following PGT-A in women ≤ 
40 years compared to a group not receiving PGT-A. Furthermore, implantation and live birth rates 
were unchanged across female age following PGT-A.31 From a purely biological perspective, 
selecting euploid embryos should increase clinical success rates on a per transfer basis, but factors 
such as quality of embryo culture and biopsy technique, as well as diagnostic methods applied, 
may explain the somewhat divergent findings currently reported in the literature.
The application of PGT-A in patients referred to PGT for inherited disorders has not been 
systematically reviewed. Hence, we looked at the available literature reporting on concurrent 
PGT-A and PGT-M/SR with the aim of investigating the prevalence of aneuploidy and clinical 
effect of aneuploidy screening. Since blastocyst stage biopsy has been shown to be superior to 
cleavage stage biopsy with respect to analytic precision and clinical outcomes,14,20–25 only studies 
performing biopsy on blastocysts were considered relevant for this review.  
MATERIAL AND METHODS
This review was performed and written in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including the PRISMA flowchart 
and checklist. 
In- and exclusion criteria
Inclusion criteria were 1) that PGT-SR or PGT-M was performed in combination with PGT-A and 
2) that aneuploidy rates and/or clinical outcomes were reported. Clinical outcomes were defined as 
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heartbeat/clinical pregnancy, ongoing pregnancy, miscarriage/spontaneous abortion, ongoing 
pregnancy or live birth/delivery rate reported on a per transfer basis. 
Exclusion criteria were 1) Case-studies, 2) Studies not performing trophectoderm biopsy or where 
aneuploidy or clinical outcomes specific for trophectoderm biopsies could not be extracted, 3) 
Reviews, 4) Redundant publications (Same data used for two publications) and 5) Studies lacking 
important meta data relevant for interpreting and/or understanding the data. 
Literature search 
Searches were performed in PubMed and Embase to identify publications regarding concurrent 
PGT-A and PGT-M/SR. This was done using separate comprehensive search strategies for 
PubMed and Embase. The search strings can be seen in Supporting Information Appendix S1. 
Abstracts were screened by C.L.F. Toft and full text reviewed by I.S. Pedersen and C.L.F. Toft, 
who also agreed on the final selection of papers. 
Data extraction pooling
Data was extracted directly from the articles and/or supplementary material when needed. P-
values were reported here as reported by the authors in the original article. In case p-values were 
not reported, they were calculated where needed. In cases where data or statistical calculations 
seemed to have been misreported, the corresponding author was contacted for clarification. 
Authors were not contacted to obtain meta data. Data was pooled and weighted regarding the 
number of embryos analyzed to obtain a weighted average aneuploidy rate and weighted average 
proportions of suitable embryos prior to and post PGT-A. Even though measured aneuploidy rates 
are in theory affected by the platform used for PGT-A, the potential differences caused by 
different platforms were considered neglectable. Hence, weighted aneuploidy rates were 
performed across studies utilizing different PGT-A platforms. Since the aim was to report on 
aneuploidy in PGT in general, differences in mean female age (MFA) was not considered an issue 
when calculating the weighted aneuploidy rate. Data pooling with respect to clinical outcomes was 
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Tools for assessment of risk of bias are mainly developed for randomized controlled trials, cohort 
and case-control studies. Since the vast majority of studies included in this review were case series 
with no reference group, no formal assessment of risk of bias was performed, as the risk would in 
any case be considerable. 
Statistical analyses
All statistical analyses were performed using R version 1.1.453 (https://support.rstudio.com/). 
Testing for the null hypothesis that proportions (both aneuploidy and clinical outcomes) in two 
groups were the same were performed using chi-squared test or Fisher’s exact test. P-values less 
than 0.05 were considered statistically significant. 
RESULTS
Literature search and study characteristics
A total of 1717 publications were identified through Medline (840) and PubMed (877). Screening 
for duplicates resulted in 1291 unique publications. Title and abstract screening resulted in 73 
papers. Full text screening resulted in 26 publications fulfilling the inclusion criteria 18,32,41–50,33,51–
56,34–40. Interestingly, no randomized controlled trials were identified. Three historical cohort 
studies with a reference group not receiving aneuploidy screening were identified, while the 
remaining studies were case series without a reference group. The search was last updated on the 
first of July 2019. A flow diagram of the screening process in shown in Figure 1. Table 1 
summarizes the main characteristics of the 26 studies included in this review in chronological 
order of publication date. 
The included studies were published between 2011 and 2019. The number of patients receiving 
trophectoderm biopsy was not available in 4 studies. MFA of patients receiving trophectoderm 
biopsy was available in 15 studies and ranged from 29.2 to 38.1 years. The number of embryos 
successfully analyzed for both aneuploidy and genetic disorder ranged from 12 to 1498. No 
studies reported performing sequential biopsies or rebiopsy. All included studies reported 
aneuploidy rates. 17 studies reported clinical outcomes with three retrospective studies included a 
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array/karyomapping and quantitative PCR were used for aneuploidy detection (Table 1). 
Diagnosis of x-linked disorders was classified as PGT-M in all of the included studies.
Prevalence of aneuploidy in patients carrying or affected by a genetic disorder
The reported aneuploidy rates are listed in Table 1 and illustrated in Figure 2. The aneuploidy rate 
ranged from 17.2 to 83.3 %. The weighted average aneuploidy rate of the 7749 embryos was 34.1 
% (95 % CI; 33.1 % to 35.2 %) (Figure 2, top bar). For PGT-M, aneuploidy ranged from 19.0 to 
83.3 % with a weighted average of 35.9 %. For PGT-SR, aneuploidy ranged from 17.2 to 53.3 % 
with a weighted average of 32.5 %. Comparing PGT-M and PGT-SR there was a small but 
statistically significant difference between the two groups with aneuploidy being more prevalent in 
the PGT-M group (P = 0.002). 
The effect of PGT-A on the number of transferable embryos
The percentage of embryos suitable for transfer prior to and post PGT-A are shown in Figure 3A. 
Combining the data, the weighted average number of embryos being suitable for transfer prior to 
and post PGT-A dropped from 57.5 to 37.2 % (95 % CI; prior: 56.3 % to 58.6 %, post: 36.1 % to 
38.4 %) (Figure 3A, top bar). 17 of 22 studies reported a statistically significant difference in the 
number of suitable blastocysts for transfer prior to and post PGT-A (Figure 3A). Comparing PGT-
M and PGT-SR, there were no statistically significant difference between the percentage of 
blastocysts suitable for transfer prior to and post PGT-A (P = 0.8 and P = 0.6, respectively, Figure 
3B). 
The effect of PGT-A on the percentage of cycles with no transfer
Screening for aneuploidy significantly increased the percentage of non-transferable embryos. In 
one study, embryo transfer was performed in 81 % of cycles (1688/2084) while only 67 %of 
cycles had transferable embryos following screening for aneuploidy (212/317).54 In another study, 
out of 304 cycles, 71 % of cycles had suitable embryos for transfer following PGT-M/SR, which 
was reduced to 60 % following aneuploidy screening.36 Minasi et al. reported the percentage of 
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affected by monogenic disorders and structural rearrangements. The remaining studies did not 
provide any data on the increase in frequency of cycles with no transfer following aneuploidy 
screening. 
Clinical outcomes of concurrent PGT-A and PGT-M/SR
Of the reviewed literature, 17 publications reported on clinical outcomes following PGT-A (Table 
1). Only three studies included a reference group not receiving PGT-A (Table 1, Figure 4).34,50,54  
The average number of embryos transferred in the PGT-A and reference group for the three 
historical cohort studies are shown in Figure 4D. Only Hou et al. performed single embryo 
transfer in both groups where the Goldman et al. and Rechitsky et al. transferred more embryos in 
the reference group compared with the PGT-A group. Of the three studies, one did not achieve 
statistically significant results (Figure 4B).50 The other two studies reported significantly improved 
clinical outcomes compared to the reference group (Figure 4A and C).34,54 The study by Hou et al. 
contained age-matched cohorts (MFA of 29.02 vs. 29.34, P = 0.328) while the study by Rechitsky 
et al. did not disclose the MFA of the reference group. Hence, it cannot be excluded that the 
reported clinical effect from PGT-A reported by Rechitsky et al. might be caused by comparison 
of non-age-matched cohorts. Furthermore, it should be noted that the study by Rechitsky et al. 
performed both cleavage and blastocyst stage biopsy and even though clinical outcomes following 
blastocyst biopsy could be deferred from the article in case of the PGT-A data, this was not 
possible for the reference group. Of the 196 embryo transfers, 158 and 38 were following 
blastocyst and cleavage stage biopsy, respectively. Contrary to previous reports in the 
literature,14,20,22,23 the data from Rechitsky et al. showed no significant differences in clinical 
outcomes between the two biopsy stages for any of the three parameters reported (P > 0.95 for all 
three parameters). 
Mosaicism
Of the 26 publications, six studies reported on the prevalence of mosaicism. One publication 
reported mosaicism on a per chromosome level only.51 The remaining five publications reported 
on mosaicism ranging from 0 % (0/175 and 0/18 embryos) to 10.8 % (11/102 embryos) with the 
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studies details their classification and transfer policy with respect to mosaic embryos, 34,39,51 with 
two never transferring mosaic embryos,34,39 and one considering mosaic embryos for transfer in 
the case that there was no euploid embryos available and that the level of mosaicism was 40 % or 
less. 51 The remaining three studies do not detail their classification of or transfer policy with 
respect to mosaic embryos. 36,43,46
DISCUSSION
This review presents data from the 26 publications currently published about concurrent PGT-A 
and PGT-M/SR, which report on aneuploidy rates and/or clinical outcomes. Only three studies 
included a reference group. All three were historical cohort studies. 
Despite the relatively young age of the patient cohort (ranging from 29.2 to 38.1), a significant 
proportion of embryos (34.1 %, 95 % CI; 33.1 % to 35.2 %) were aneuploid, indicating that a 
substantial fraction of embryos derived from couples seeking PGT for inherited disorders might be 
unsuitable for transfer. A wide range of aneuploidy frequencies were observed ranging from 17.2 
to 83.3 %. Removing the bias introduced by analyzing a small number of embryos (by including 
studies of more than 100 embryos) resulted in an aneuploidy frequency from 21.5 to 56.5 %. This 
is still a wide range that cannot be explained simply by differences in MFA, but more likely by 
variations in the embryo handling procedures and diagnostic setups of individual clinics and 
laboratories. This underlines the need for further evaluation of the use of PGT-A. 
Although aneuploidy was significantly more prevalent in PGT-M compared to PGT-SR (35.9 
versus 32.5 %, P = 0.002) this finding is of little value since the data does not allow control for 
confounding variables, the most important being female age in the case of aneuploidy. 
Aneuploidy is considered a significant contributor to implantation failures experienced during 
ART, but it is unknown if infertile couples are especially prone to create aneuploid embryos 
compared to fertile couples. Since most couples referred for PGT-M/SR are fertile, comparison of 
the ART and PGT cohort might help answer this question. Although the data presented here does 
not allow a strict age-matched comparison of prevalence of aneuploidy between the fertile (PGT-
M/SR) and infertile patient (ART) cohorts, the weighted aneuploidy rate of 34.1 % in the PGT-
M/SR cohort is comparable to that previously reported in a large ART study within the same age 
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PGT-A substantially increases the number of non-transferable embryos compared to PGT-M/SR 
alone (Figure 3A). All but four studies reported a statistically significant reduction in the 
percentage of embryos being suitable for transfer before and after PGT-A. The remaining four 
studies most likely failed to reach statistically significant differences due to the small sample 
size.43,44,53,55 As a direct consequence of this, opting for PGT-A will most likely increase the risk 
of experiencing a cycle with no transferable embryos, and patients should therefore be informed 
about this risk during counseling on when to opt for PGT-A or not as well as about the on-going 
discussion of a clinical effect. This risk is expected to increase with both female age (as 
aneuploidy increases) and with decreasing ovarian reserve, meaning that risk counseling should 
consider these factors. 
With respect to clinical outcomes, the currently published studies either lack an (age-matched) 
reference group, proper sample size and/or control of confounding variables such as the stage of 
biopsy, MFA and the number of embryos transferred per transfer, to allow a proper evaluation of 
the effect of PGT-A. We only identified three studies which had included a reference group of 
which two reported improved clinical outcomes,34,54 while one failed to show an effect.50 They 
were all historical cohort studies. One study performed both cleavage and blastocyst stage biopsy, 
of which the ratio with respect to the reference group was undisclosed,54 complicating comparison 
as implantations rates are affected by the stage of embryo biopsy.24,25 The study by Goldman et al. 
included only 32 and 8 patients in the PGT-A and reference group, respectively, making it difficult 
to detect small but significant differences. The last study indicated a benefit from PGT-A with 
respect to clinical outcomes.34 Comparison to clinical outcomes reported in most recent report 
from the ESHRE PGT consortium would have been interesting but are not meaningful due to the 
degree of heterogeneity between the two datasets. In conclusion, randomized controlled trials of 
sufficient size are needed to draw final conclusions on a clinical effect of PGT-A. 
The issue of PGT-A is presently intensely discussed. In that regard, it is important that any debate 
and evaluation of PGT-A with respect to clinical outcomes is based and performed on a per 
transfer basis. This is important, since the purpose of PGT-A is to aid in prioritization of embryos 
for transfer. Hence, PGT-A is unlikely to enhance cumulative live birth rates, as cumulative 
transfer will ultimately lead to transfer of the “best” embryo in a given embryo cohort. In worst 
case, PGT-A might even decrease cumulative live birth rates as misdiagnosis can lead to viable 
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time to live birth. One of the main arguments against the use of PGT-A is the current limited 
knowledge on how to interpret the result of a trophectoderm biopsy due to embryonic mosaicism, 
the presence of one or more genetically distinct cells lines within the embryo, which is reported to 
affect 3-24 % of human blastocysts.21 This may lead to false conclusions e.g. in case of isolated 
aneuploid groups of cells within the trophectoderm in an embryo with an euploid inner cell mass 
or vice versa. Only a few of the included publications report on mosaicism making it difficult to 
assess the impact. On top, information regarding how mosaic embryos are classified, and their 
corresponding transfer policy were rarely clear or provided. It should be kept in mind that 
aneuploidy rates will differ depending on whether mosaic embryos are classified as aneuploid or 
not, which is why this should always be detailed. The few rates of mosaicism reported in the 
included studies is in line with previous studies, showing that mosaic embryos constitute a small 
but potentially significant part of the embryo cohort, with potential to produce liveborn 
offspring.57 In general, if aneuploidy screening is performed, and there is no euploid embryos 
available, mosaic embryos could be prioritized based on the chromosome(s) affected by 
aneuploidy, the type of aneuploidy and the degree of mosaicism detected,57–60 preferably 
according to guidelines presented by the Preimplantation Genetic Diagnosis International Society 
(PGDIS) and Controversies in Preconception, Preimplantation and Prenatal Diagnosis 
(COGEN).61,62 In general, each center utilizing PGT-A should develop evidence-based guidelines 
for embryo prioritization to ensure standardization of the treatment and transparency to both 
patients and piers. 63 Given the multitude of different factors influencing clinical outcomes 
following PGT-A, including the complex issue of mosaicism, even well documented guidelines 
need validation and may not be transferable from one center to another. Hence, comprehensive 
validation of PGT-A prior to clinical implementation seems necessary. Prospective, blinded, non-
selection studies as performed and described by Scott et al. seems essential to evaluate the 
predictive value of PGT-A on a per center basis.64 Such a study design allows direct measurement 
of the predictive value of ploidy calls with regard to their effect on clinical outcomes and hence 
provide the best possible data to guide the decisions on whether to apply PGT-A or not in PGT-
M/SR in a given clinical setting. The predictive values might even be provided to patients when 
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CONCLUSION
The current published literature reveals that aneuploidy affects one third of preimplantation human 
blastocysts, which upon transfer might lead to implantation failure, abortion or birth of affected 
children. Given these numbers, PGT-A concurrently with PGT-M/SR should in theory be able to 
enhance clinical outcomes on a per transfer basis, but the current available literature is sparse or of 
insufficient quality. Importantly, studies should seek to minimize impact from confounding 
variables such as the stage of biopsy and number of embryos transferred between the treatment 
and control group as well as seeking to compare age-matched cohorts. Although the available data 
may indicate an improvement in crude clinical outcome in accordance with expectations based on 
biological facts, routine use of PGT-A concurrently with PGT-M/SR with the aim of improving 
clinical outcomes are not supported by substantial evidence. Hence, randomized controlled trials 
are warranted and, preferably, should be accompanied by on site non-selection studies prior to 
implementation of PGT-A.
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Supporting information legend:
Appendix S1. PubMed and Embase search strings.
Table and figure legends:
Table 1: Overview of the articles fulfilling criteria for inclusion. 
Figure 1: PRISMA flowchart describing the screening process. PGT-M, preimplantation genetic 
testing for monogenic disorders; PGT-SR, preimplantation genetic testing for structural 
rearrangements; PGT-A, preimplantation genetic testing for aneuploidy.
Figure 2: Aneuploidy rates reported in human preimplantation blastocyst derived from couples 
receiving preimplantation genetic testing for inherited disorders. Aneuploidy rates for individual 
studies and weighted average (Top bar) is shown. Bars are ordered in descending order by the 
number of embryos analysed. MFA, mean female age.
Figure 3A: Proportion of embryos being suitable for transfer prior to (green) and post (blue) 
aneuploidy screening in couples receiving preimplantation genetic testing for inherited disorders. 
Individual studies and weighted average (Top bar) are shown sorted in descending order by the 
number of embryos analysed. P-values were calculated using Chi square test.  PGT-A, 
preimplantation genetic testing for aneuploidy.
Figure 3B: The effect of aneuploidy screening on the proportion of embryos being suitable for 
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structural rearrangements (green). P-values were calculated using Chi square test.  PGT-M: 
Preimplantation genetic testing for monogenic disorder; PGT-SR: Preimplantation genetic testing 
for structural rearrangements.
Figure 4: Clinical outcomes in the reference (blue) and PGT-A (green) groups reported by the 
three historical cohort studies by A) Rechitsky et al.,54 B) Goldman et al.,50 and C) Hou et al..34 D) 
The average number of embryos transferred in the reference and PGT-A groups in the four 
historical cohort studies. P-values marked with * were reported by the authors, while unmarked p-
values were calculated for the purpose of this review using two sided Fischer’s exact test. It should 
be noted that the p-value for differences in live birth rates reported by Goldman et al. was 1, which 
is impossible with the outcomes given. 50 Hence the correct p-value was calculated, and the 
corresponding author contacted to verify the correct P-value, which she reported as 0.43 in 
agreement with our calculation. Underlying numbers were not reported by Goldman et al., which 
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Alfarawati et al., 2011
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PGT-SR 8 NA 56 CGH + aCGH 44.6 No No 
Treff et al., 2011
18 
PGT-SR 18/15 NA/31.2 122 SNP array 33.6 Yes
a,b,c,e,f 
No 
Colls et al., 2012
48 
PGT-SR 10 33.4 75 aCGH 53.3 No No 
Tan et al., 2013
38 
PGT-SR 169 30.2 717 SNP array 26.2 Yes
b,c,d,f 
No 
Treff et al., 2013
53 
PGT-M 6 NA 21 NGS 19.0 No No 
Yin et al., 2013
55
 PGT-SR 14 NA 29 NGS 17.2 No No 
Tan et al., 2014
32 
PGT-SR 297 30.9 1217 NGS or SNP array 27.0 Yes
b,c,d,e,f 
No 
Tobler et al., 2014
35 
PGT-SR NA NA 172 SNP array or aCGH 21.5 Yes
3 
No 
Bono et al., 2015
39 
PGT-SR 28 NA 102 NGS 51.0 No No 
Fan et al., 2015
43 
PGT-SR 3 NA 18 NGS 33.3 No No 
Idowu et al., 2015
49 
PGT-SR NA 33.7 102 SNP array 24.0 Yes
a,c,f 
No 
Rechitsky et al., 2015
54 
PGT-M NA NA 1498 SNP array 33.6 Yes
d,f,g 
Yes 
Goldman et al., 2016
50 






Zhang et al., 2016
51 
PGT-SR 16 31.9 74 NGS 29.7 No No 
Zimmerman et al., 2016
56 
PGT-M 43 33.4 300 qPCR 28.3 Yes
a,b,c,f 
No 
Ben-Nagi et al., 2017
47 
PGT-M/PGT-SR 67 NA 422 Karyomapping 30.3 Yes
b,d,e 
No 
Christodoulou et al., 2017
41 
PGT-SR 34 32.5 195 aCGH 37.4 Yes
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No 
Minasi et al., 2017
36 
PGT-M/PGT-SR 227 35.4/38.1 1067 aCGH 50.6 Yes
a,c,e,f 
No 
Xu et al., 2017
44 
PGT-SR 16 NA 108 NGS 22.4 Yes
f 
No 
Zhang et al., 2017
52 
PGT-SR 11 29.2 68 SNP array 29.4 Yes
f 
* No 
Del Rey et al., 2018
42 
PGT-M 9 NA 12 NGS 83.3 No No 
Li et al., 2018
46 
PGT-M 36 31.9 175 Karyomapping 22.9 Yes
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No 
Volozonoka et al., 2018
40 
PGT-M 9 35.3 32 aCGH 37.5 Yes
g
 ** No 
Wang et al., 2018
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 ** No 
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Hou et al., 2019
34 
PGT-M 98 30.9 646 Karyomapping or NGS 33.6 Yes
b,d,e,f 
Yes 




Gestational sacs/implantation rate; 
c









Pregnancy (Not defined) 
*Report on outcomes from embryo transfer in one patient 
**Report on outcomes from embryo transfers in two patients 
Abbreviations: aCGH: Array comparative genomic hybridization; CGH: Comparative genomic hybridization; hCG: Human chorionic gonadotropin; NA: Not available; NGS: Next generation 
sequencing; PGT-A: Preimplantation genetic testing for aneuploidy; PGT-M: Preimplantation genetic testing for monogenic disorders; PGT-SR: Preimplantation genetic testing for structural 











Screening flow diagram 
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Total number of publications identified 
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Exclusion of publications based on 
title and abstract 
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Unique full-text publications assessed for eligibility 
(n = 73) Full-text records excluded, with 
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(n = 47) 
- Case studies (n = 25) 
- PGT-A not performed on 
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- Missing significant meta data 
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- Redundant publication (n = 1) 
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- Not original article (n = 1) 
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abortions/pregnancy
Clinical outcomes reported by Goldman et al. 2016
B)
